New drug LM-108 shows promise in early trial for Hard-to-Treat cancers
NCT ID NCT05518045
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study is testing an experimental drug called LM-108, given alone or with other cancer treatments, in about 392 people with advanced solid tumors that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose, and to see if it can shrink tumors. This is an early-phase trial, so the focus is on safety and initial signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.